Salarius Pharmaceuticals, Inc. Names Nadeem Mirza as Senior Vice President Clinical Development
July 23, 2020 at 08:00 am
Share
Salarius Pharmaceuticals, Inc. announced that Nadeem Q. Mirza, M.D., M.P.H., has joined Salarius as Senior Vice President Clinical Development. With 28-years of industry and cancer research experience, Dr. Mirza will head the company’s clinical development and regulatory teams. He joins Salarius as the company advances its lead drug candidate, seclidemstat, towards important clinical milestones in two Phase 1/2 clinical trials now underway for Ewing sarcoma and advanced solid tumors (AST). Over the past 16 years, Dr. Mirza has brought his clinical development and medical affairs expertise to multiple companies and development opportunities in the oncology space, spanning emerging to globally established companies and early-stage to commercial-stage drug programs. Prior to joining Salarius, Dr. Mirza served as Chief Medical Advisor at TRIGR Therapeutics, Inc. and before that as Senior Vice President, Corporate Medical Affairs at Verastem Oncology, where he oversaw the launch of Copiktra®, an oral medication for relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma. Previously, Dr. Mirza held senior positions at several major biopharmaceutical companies and participated in launch activities for seven other cancer and leukemia medications, including Campath®, Abraxane®, Nexavar®, Clolar®, Zaltrap®, Jevtana®, and Venclexta®. He served as Global Head Hematology and Solid Tumors at AbbVie Oncology and Vice President, Head of Oncology, North America Medical Affairs at Sanofi Oncology. Dr. Mirza also held leadership roles in medical affairs and clinical development at Genzyme/Sanofi, Onyx Pharmaceuticals, Inc., Abraxis Oncology, and Berlex Oncology. In addition to his significant industry accomplishments, Dr. Mirza spent 12 years as a researcher at MD Anderson Cancer Center in Houston where he participated in research in infectious disease, bone marrow transplantation and breast cancer that led to 59 peer-reviewed publications on clinical outcomes. From 1987 to 1991, he served as a primary care physician in Pakistan after earning a medical degree from the University of Punjab in Lahore, Pakistan.
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening and further optimization with structure-activity relationship studies.
SALARIUS PHARMACEUTICALS, INC. 
